Building on these findings, we developed patient-derived tissue (PDT) models that preserved the cellular heterogeneity of clinical samples, encompassing tumor cells, CD45+ immune cells, CD3+ T cells, and other cell populations. This evidence concerns the gene PTPRC and neoplasm.